Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Price for REN (US) takeover by Gambro has risen:

This article was originally published in Clinica

Executive Summary

Swedish Gambro's US subsidiary, Cobe Laboratories, and REN (US) have signed a definitive merger agreement at a higher price than announced in July. Instead of $18 a share, REN shareholders will receive $20 per share in cash (see Clinica No 664, p 16). Even before the tender offer, Cobe owned 53% of REN. When the merger is complete, REN will become a wholly-owned subsidiary of Cobe.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT093275

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel